MedTrace Logo

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

NCT00406094 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-01-16

No results posted yet for this study

Summary

The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.

Conditions

  • Rhinitis

Interventions

DRUG

montelukast

10mg

DRUG

placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Jonathan A Bernstein, MD · Bernstein Allergy Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406094 on ClinicalTrials.gov